US Patent Issued to Kadmon on Oct. 20 for "Method of administering belumosudil for treatment of chronic graft versus host disease" (Massachusetts Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,766,143, issued on Oct. 20, was assigned to Kadmon Corp. LLC (Morristown, N.J.).

"Method of administering belumosudil for treatment of chronic graft versus host disease" was invented by David Eiznhamer (Cambridge, Mass.) and Heidi Krenz (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the identification, such as by ceasing administration when the infection is a...